Clinical Trials Directory

Trials / Completed

CompletedNCT01812746

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
42 (actual)
Sponsor
BIND Therapeutics · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety BIND-014 in patients with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

Interventions

TypeNameDescription
DRUGBIND-014

Timeline

Start date
2013-04-01
Primary completion
2016-04-01
Completion
2016-04-01
First posted
2013-03-18
Last updated
2016-04-15

Locations

8 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01812746. Inclusion in this directory is not an endorsement.